Key clinical point: Inotuzumab ozogamicin shows promising safety and efficacy in children and young adults with R/R B-ALL.
Major finding: The overall CR/CRi rate after 1 cycle of treatment was 58.3%.
Study details: A phase 2 study of 48 patients.
Disclosures: COG AALL1621 was funded by NCTN grants, St. Baldrick’s Foundation, and Pfizer. Dr. O’Brien reported research funding from Pfizer, Celgene, AbbVie, Amgen, Bristol-Myers Squibb, and BTG.
O’Brien M et al. ASH 2019, Abstract 741.